Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir) (LEONCET2)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT00657930

NN304-3526

Details and patient eligibility

About

This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard®, Humulin® N (NPH insulins) as basal insulin as part of their ICT under normal clinical practice conditions in Hungary.

Enrollment: 2,289 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetic subjects on intensive insulin treatment (ICT)
• Eligibility for once daily insulin detemir administration
• Informed consent obtained before any observation-related activities

Exclusion criteria

• Known or suspected allergy to insulin detemir
• Subjects previously enrolled in the observation
• Women who are pregnant, breast feeding or have the intention of becoming pregnant within 6 months.

Trial design

2,289 participants in 1 patient group

A

Treatment:

Drug: insulin detemir